United Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by Achmea Investment Management B.V.

Achmea Investment Management B.V. raised its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 61.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 59,180 shares of the biotechnology company's stock after buying an additional 22,434 shares during the period. Achmea Investment Management B.V. owned approximately 0.13% of United Therapeutics worth $18,243,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Atria Wealth Solutions Inc. purchased a new position in shares of United Therapeutics during the 4th quarter worth approximately $412,000. Amalgamated Bank increased its position in United Therapeutics by 2.8% during the fourth quarter. Amalgamated Bank now owns 22,167 shares of the biotechnology company's stock worth $7,821,000 after buying an additional 602 shares in the last quarter. Denali Advisors LLC purchased a new position in United Therapeutics during the fourth quarter worth $495,000. Oregon Public Employees Retirement Fund lifted its position in shares of United Therapeutics by 0.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock valued at $3,214,000 after acquiring an additional 33 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new stake in shares of United Therapeutics during the fourth quarter valued at $22,658,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other United Therapeutics news, Director Nilda Mesa sold 645 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the completion of the transaction, the director now owns 4,883 shares of the company's stock, valued at $1,416,021.17. This represents a 11.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO James Edgemond sold 12,000 shares of the business's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the sale, the chief financial officer now directly owns 8,118 shares in the company, valued at approximately $2,641,353.66. This represents a 59.65% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 80,681 shares of company stock worth $24,177,219. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Trading Down 0.7%

Shares of UTHR opened at $284.09 on Friday. The firm has a market cap of $12.82 billion, a price-to-earnings ratio of 11.34, a PEG ratio of 6.26 and a beta of 0.57. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82. The stock has a 50 day moving average of $301.13 and a 200-day moving average of $325.65.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping the consensus estimate of $6.29 by $0.34. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The business had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same quarter in the prior year, the company posted $6.17 earnings per share. The company's quarterly revenue was up 17.2% compared to the same quarter last year. On average, sell-side analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on UTHR shares. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. JPMorgan Chase & Co. dropped their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Bank of America cut their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a report on Wednesday, June 11th. Cantor Fitzgerald initiated coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target for the company. Finally, Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $393.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.